BR112021017405A2 - Métodos e composições para tratar câncer - Google Patents
Métodos e composições para tratar câncerInfo
- Publication number
- BR112021017405A2 BR112021017405A2 BR112021017405A BR112021017405A BR112021017405A2 BR 112021017405 A2 BR112021017405 A2 BR 112021017405A2 BR 112021017405 A BR112021017405 A BR 112021017405A BR 112021017405 A BR112021017405 A BR 112021017405A BR 112021017405 A2 BR112021017405 A2 BR 112021017405A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- methods
- fgfr3
- compositions
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940125832 FGFR3 inhibitor Drugs 0.000 abstract 3
- 206010005003 Bladder cancer Diseases 0.000 abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 2
- 239000012270 PD-1 inhibitor Substances 0.000 abstract 1
- 239000012668 PD-1-inhibitor Substances 0.000 abstract 1
- 229940123751 PD-L1 antagonist Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229940121655 pd-1 inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
métodos e composições para tratar câncer. o presente pedido fornece composições, métodos e kits para o tratamento de câncer, incluindo câncer de bexiga, tal como câncer de bexiga luminal, usando um inibidor de fgfr3 em combinação com um inibidor de checkpoint. em algumas modalidades, o câncer expressa fgfr3 de tipo selvagem. o inibidor de fgfr3 pode ser um inibidor de fgfr3 antagonista, tal como um anticorpo de fgfr3 antagonista. o inibidor de checkpoint pode ser um inibidor de pd1, incluindo um anticorpo de pd1 ou ligante de pd1 (pd-l1), tal como um anticorpo de pd1 ou pd-l1 antagonista.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856216P | 2019-06-03 | 2019-06-03 | |
| US201962907504P | 2019-09-27 | 2019-09-27 | |
| PCT/US2020/020846 WO2020180898A1 (en) | 2019-03-01 | 2020-03-03 | Methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017405A2 true BR112021017405A2 (pt) | 2021-12-07 |
Family
ID=77920310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017405A BR112021017405A2 (pt) | 2019-06-03 | 2020-03-03 | Métodos e composições para tratar câncer |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2023514795A (pt) |
| KR (1) | KR20220016803A (pt) |
| CN (1) | CN113710244A (pt) |
| BR (1) | BR112021017405A2 (pt) |
| CA (1) | CA3131880A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134234A1 (en) * | 2015-02-19 | 2016-08-25 | Bioclin Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
| CN110785184A (zh) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法，组合物和试剂盒 |
-
2020
- 2020-03-03 CN CN202080030176.5A patent/CN113710244A/zh active Pending
- 2020-03-03 CA CA3131880A patent/CA3131880A1/en active Pending
- 2020-03-03 BR BR112021017405A patent/BR112021017405A2/pt not_active IP Right Cessation
- 2020-03-03 KR KR1020217031144A patent/KR20220016803A/ko unknown
- 2020-03-03 JP JP2021551871A patent/JP2023514795A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3131880A1 (en) | 2020-09-10 |
| KR20220016803A (ko) | 2022-02-10 |
| JP2023514795A (ja) | 2023-04-11 |
| CN113710244A (zh) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210013A (es) | Inhibidores de pd-1/pd-l1 | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| BR112018016310A2 (pt) | métodos para uso de agonistas de fxr | |
| MX2017013613A (es) | Neoepitodos de cancer. | |
| AU2017266951A1 (en) | Use of Glutamate modulating agents with Immunotherapies to treat cancer | |
| BR112019005823A2 (pt) | tratamento para enxaqueca refratária | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| CO2018000244A2 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| BR112017017700A2 (pt) | métodos, composições e kits para tratamento do câncer | |
| MX2018005991A (es) | Cumplimiento de geolocalizacion para una fuerza de trabajo movil. | |
| BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
| BR112014019331A8 (pt) | anticorpos para cd47 e métodos de uso desses | |
| EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| CR10325A (es) | Diagnosticos y tratamientos para tumores | |
| CU20110029A7 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 | |
| BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| MX2017012113A (es) | Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. | |
| CL2021000178A1 (es) | Compuestos de piridin-2-ona útiles como antagonistas de smarca2 | |
| CL2008002782A1 (es) | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. | |
| AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
| ZA202107139B (en) | Methods and compositions for treating cancer | |
| UY35803A (es) | Recubrimiento de alginato para tratamiento de esquejes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2735 DE 06-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |